IntelliPharmaCeutics International (IntelliPharmaCeutics International) Total Liabilities : $14.44 Mil (As of Aug. 2023)

View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Total Liabilities?

IntelliPharmaCeutics International's Total Liabilities for the quarter that ended in Aug. 2023 was $14.44 Mil.

IntelliPharmaCeutics International's quarterly Total Liabilities increased from Feb. 2023 ($12.53 Mil) to May. 2023 ($12.72 Mil) and increased from May. 2023 ($12.72 Mil) to Aug. 2023 ($14.44 Mil).

IntelliPharmaCeutics International's annual Total Liabilities increased from Nov. 2020 ($9.70 Mil) to Nov. 2021 ($10.25 Mil) and increased from Nov. 2021 ($10.25 Mil) to Nov. 2022 ($12.01 Mil).

IntelliPharmaCeutics International Total Liabilities Historical Data

The historical data trend for IntelliPharmaCeutics International's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Total Liabilities Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Total Liabilities

Get a 7-Day Free Trial

7.37

7.49

9.70

10.25

12.01

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
Total Liabilities	Get a 7-Day Free Trial															11.59	12.01	12.53	12.72	14.44

IntelliPharmaCeutics International Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

IntelliPharmaCeutics International's Total Liabilities for the fiscal year that ended in Nov. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	12.009	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	12.01

Total Liabilities	=	Total Assets (A: Nov. 2022 )	-	Total Equity (A: Nov. 2022 )
	=	1.432	-	-10.577
	=	12.01

IntelliPharmaCeutics International's Total Liabilities for the quarter that ended in Aug. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	14.442	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	14.44

Total Liabilities	=	Total Assets (Q: Aug. 2023 )	-	Total Equity (Q: Aug. 2023 )
	=	1.566	-	-12.876
	=	14.44

IntelliPharmaCeutics International Total Liabilities Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

I4AA:Germany IPCI:Canada

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.